Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3529-3535

  Wang, Ching Y ^a,d   Jones, Richard F ^a   Debiec Rychter, Maria ^b   Soos, Gyorgyike ^c   Haas, Gabriel P ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Bladder cancer; Genotype; NAT; Prostate cancer; Risk

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; CIGARETTE SMOKE;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CIGARETTE SMOKING; CLINICAL ARTICLE; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLTRANSFERASES; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 0036875533     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chun T: Coincidence of bladder and prostate cancer. J Urology 157: 65-67, 1997.
2. Kleinerman R, Liebermann J and Li F: Second cancer following cancer of the male genital system in Connecticut. Natl Cancer Inst Monographs 68: 139-147, 1985.
3. Montie J, Wood D, Pontes J, Boyett J and Levin H: Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 63: 381-385, 1989.
4. Pritchett T, Moreno J, Warner N, Lieskovsky G, Nichols P, Cook B and Skinner D: Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 139: 1214-1216, 1988.
5. Howard L, Bateman H, Kasmis B, Romberger C, Zeleniuch-Jocquotte D, Steafather H and Hwang S: Multiple primary cancer among patients with prostate cancer. Proc Am Soc Clin Oncol 13: 235, 1994.
6. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, Hasegawa R, Imaida K, Masumoto K, Wakabayashi K, Sugimura T and Ito N: The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo4,5-bpyridine (PhIP) derived from cooked foods. Cancer Res 57: 195-198, 1997.
7. King C, Land S, Jones R, Debiec-Rychter M, Lee M and Wang C: Role of acetyltransferases in the metabolism and carcinogenicity of aromatic amines. Mutation Res 376: 123-128, 1997.
8. Cartwright R, Glashan R, Rogers H, Ahmad R, Barham-Hall D, Higgin E and Kahn M: Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842-845, 1982.
9. Risch A, Wallace D, Bathers S and Sim E: Slow N-acetylation genotype is a suceptibility factor in occupational and smoking related bladder cancer. Human Molecular Genetics 4: 231-236, 1995.
10. Hirvonen A: Chapt. 20. Polymorphic NATs and cancer predisposition. IARC Scientific Publication 148: 251-270, 1999.
11. Poljak M and Barlic J: Rapid simple method of extracting DNA from archival Papanicolaou-stained cervical smears. Acta Cytologica 40: 374-375, 1996.
12. Bell D, Stephens E, Castranio T, Umbach D, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H and Strange R: Polyadenylation polymorphism in the acetyltransfease 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55: 3537-3542, 1995.
13. Deitz A, Doll M and Hein D: A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 253: 219-224, 1997.
14. Grant D, Hughes N, Janezic S, Goodfellow G, Chen H, Gaedigk A, Yu V and Grewal R: Human acetyltransferase polymorphisms. Mutation Res 376: 61-70, 1997.
15. Sanger F, Nicklen S and Coulson A: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5465, 1977.
16. Jones RF, Matuszyk J, Debiec-Rychter M and Wang CY: Mutation and altered expression of p53 genes in experimental rat bladder tumor cells. Mol Carcinog 9: 95-104, 1995.
17. Orita M, Suzuki Y, Sekiya T and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989.
18. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, I.H. Kau IH, Lin BR, Lee DB, Lin J, Frankl HD, Lee HR, Hardy S, Grant DM and Haile RW: Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 8: 269-281, 1998.
19. Hein DW, Doll MA, A.J. Fretland AJI, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA and Feng Y: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42, 2000.
20. Doll M, Fretland A, Deitz A and Hein D: Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem 231: 413-420, 1995.
21. Schnakenberg E, Ehlers C, Feyeraben W, Werdin R, Hubotter R, Dreikorn K and Schloot W: Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin Genet 53: 396-402, 1998.
22. Mrozikiewicz P, Cascorbi I, Brockmoller J and Roots I: Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 59: 376-382, 1996.
23. Taylor J, Umbach D, Stephens E, Castranio T, Paulson D, Robertson C, Mohler J and Bell D: The role of N-acetylation polymorphism in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58: 3603-3610, 1998.
24. Fukutome K, Watanabe W, Shiraishi T, Murata M, Uemura H, Kubota Y, Kawamura J, Ito H and Yatani R: N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Letters 136: 83-87, 1999.
25. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE and Mack TM: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63: 963-966, 1991.
26. Tsugane S, Gotlieb SL, Laurenti R, de Souza JM and Watanabe S: Cancer mortality among Japanese residents of the city of Sau Paulo, Brazil. Int J Cancer 45: 436-439, 1990.
27. Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, Wolf CR, Autrup H and Rane A: Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 9: 333-340, 1999.
28. Felton JS, Malfatti MA, Knize MG, Salmon CIP, Hopmans EC and Wu RW: Health risks of heterocyclic amines. Mutation Res 376: 37-41, 1997.
29. Hein D: Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948: 37-66, 1988.
30. Marcus PM, Vineis P and Rothman N: NAT2 slow acetylation and bladder cancer risk: a meta analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 10: 115-122, 2000.
31. Clinton S and Giovannucci E: Diet, nutrition and prostate cancer. Ann Rev Nutrition 18: 413-440, 1998.
32. Wynder EL, Fujita Y, Harris RE, Hirayama T and Hiyana T: Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer 67: 746-763, 1991.
33. Roberts-Thomson J, Ryan P, Khoo K, Hart W, McMichael A and Butler R: Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 347: 1372-1374, 1996.
34. Wang C, Debiec-Rychter M, Schut H, Morse P, Jones R, Archer C, King C and Haas G: N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis 20: 1591-1595, 1999.
35. Lang NP, Nowell S, Malfatti MA, Kulp KS, Knize MG, Davis C, Massengill J, Williams S, MacLeod S, Dingley KH, Felton JS and Turteltaub KW: In vivo human metabolism of 214C2-amino-1-methyl-6-phenylimidazo4,5-bpyridine (PhIP). Cancer Letters 143: 135-138, 1999.